Guy Young

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (140)

• Denecimig (Mim8) prophylaxis once every 2 weeks for hemophilia A with or without inhibitors: 26-week results from FRONTIER4
  Blood Advances 2026 DOI: 10.1182/bloodadvances.2025019095
  +Save
• Cases of High-Titer Inhibitor Formation After AAV Gene Therapy for Hemophilia A
  Blood Journal 2026 DOI: 10.1182/blood.2026035372
  +Save
• Successful Use of Sutimlimab in two Pediatric Patients With Refractory Cold Antibody‐Mediated Autoimmune Hemolytic Anemia
  Pediatric Blood & Cancer 2026 DOI: 10.1002/1545-5017.70751
  +Save
• Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study
  Blood Advances 2026 DOI: 10.1182/bloodadvances.2026019931
  +Save
• T2* Magnetic Resonance Imaging Uncovers Hemosiderin Burden in Pediatric Hemophilia: A Call for Sensitive Imaging Biomarkers
  Pediatric Blood & Cancer 2026 DOI: 10.1002/1545-5017.70518
  +Save
• Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents
  American Journal of Hematology 2026 DOI: 10.1002/ajh.70372
  +Save
• New Treatment in Haemophilia: Challenges, Controversies and Uncertainties
  Haemophilia 2026 DOI: 10.1111/hae.70254
  +Save
• From nothing to abundance for hemophilia with inhibitors
  Blood 2026 DOI: 10.1182/blood.2025031960
  +Save
• Multisite validation of a venous thrombosis risk model in critically ill children through the CHAT Consortium
  Blood 2026 DOI: 10.1182/blood.2025029841
  +Save
• Emicizumab in infants: not just cost-effective but mandatory
  Blood Advances 2025 DOI: 10.1182/bloodadvances.2025017871
  +Save
• Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials
  Blood Vessels, Thrombosis & Hemostasis 2025 DOI: 10.1016/j.bvth.2025.100069
  +Save
• Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
  Guy A. Young, Kaan Kavaklı, Robert Klamroth +97 more
  Blood 2025 DOI: 10.1182/blood.2024027008
  +Save
• Deconstructing the ISTH hemophilia guidelines for the clinician
  Journal of Thrombosis and Haemostasis 2025 DOI: 10.1016/j.jtha.2024.11.015
  +Save
• Fondaparinux Approval in Pediatrics: The Story of My Third Child
  Pediatric Blood & Cancer 2025 DOI: 10.1002/pbc.31638
  +Save
• Global Comparative Antithrombin Field Study: Impact of Laboratory Assay Variability on the Assessment of Antithrombin Activity Measurement at Fitusiran Clinical Decision‐Making Points
  Haemophilia 2025 DOI: 10.1111/hae.70045
  +Save
• Invitation and welcome to the 2025 ISTH Congress
  Journal of Thrombosis and Haemostasis 2025 DOI: 10.1016/j.jtha.2025.03.033
  +Save
• Reply to Letter to the Editor: “Deconstructing the ISTH Hemophilia Guidelines for the Clinician”: comment from Mancuso-ME et al.
  Journal of Thrombosis and Haemostasis 2025 DOI: 10.1016/j.jtha.2025.02.019
  +Save
• Induction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors
  Blood Advances 2025 DOI: 10.1182/bloodadvances.2024013000
  +Save
• CHIEF: A retrospective self‐control study of children with severe hemophilia A without inhibitors comparing emicizumab to FVIII prophylaxis
  Pediatric Blood & Cancer 2024 DOI: 10.1002/pbc.31351
  +Save
• Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series
  Haemophilia 2024 DOI: 10.1111/hae.15094
  +Save